Steven J. Romano - 02 Jan 2026 Form 4 Insider Report for Silence Therapeutics plc (SLN)

Reporting relationship: EVP and Chief R&D Officer
Issuer ticker: SLN
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 16:15:13 UTC
Prior SEC filing: 22 May 2025
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Rhonda Hellums, Attorney-in-Fact

Key filing fact

Steven J. Romano filed Form 4 for Silence Therapeutics plc (SLN) on 06 Jan 2026.

Key facts

This page summarizes Steven J. Romano's Form 4 filing for Silence Therapeutics plc (SLN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 16:15.

Change

Previous filing in this sequence was filed on 22 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001639860 Primary reporting owner

Romano Steven J.

Relationship: EVP and Chief R&D Officer
Address: C/O SILENCE THERAPEUTICS PLC, 12 HAMMERSMITH GROVE, LONDON, UNITED KINGDOM
Signature: /s/ Rhonda Hellums, Attorney-in-Fact
Signature date: 06 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLN transaction Derivative

Employee Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 300,000
Exercise price: $2.05
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.